Abeona Therapeutics (ABEO) Accumulated Expenses (2010 - 2026)

Abeona Therapeutics' Accumulated Expenses history runs 15 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 32.57% year-over-year to $2.6 million in Q1 2026; TTM through Mar 2026 was $2.6 million, a 32.57% decrease from a year earlier, with the FY2025 full-year figure at $8.5 million, up 33.7% from the prior year.
• Accumulated Expenses slipped to $2.6 million in Q1 2026 per ABEO's latest filing, from $8.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $8.5 million in Q4 2025 and bottomed at $745000.0 in Q1 2022.
• The 5-year median for Accumulated Expenses is $3.1 million (2025), against an average of $3.7 million.
• Across the five-year window, Accumulated Expenses plunged 74.02% in 2022 and surged 233.05% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $2.6 million in 2022, then surged by 130.81% to $6.0 million in 2023, then rose by 5.81% to $6.3 million in 2024, then surged by 33.7% to $8.5 million in 2025, then tumbled by 69.04% to $2.6 million in 2026.
• Per Business Quant, the three latest ABEO Accumulated Expenses figures stand at $2.6 million (Q1 2026), $8.5 million (Q4 2025), and $6.9 million (Q3 2025).